NASDAQ:EGRX Eagle Pharmaceuticals Q1 2023 Earnings Results & Report $0.88 -0.01 (-0.56%) As of 03:04 PM Eastern Eagle Pharmaceuticals beat analyst expectations on both earnings and revenue in its Q1 2023 results, released May 9, 2023. The company reported EPS of $0.44 versus the $0.40 consensus estimate, while revenue of $66.31 million topped the $63.88 million estimate by $2.43 million. Research:Profile Earnings Announcement Details QuarterQ1 2023Report DateMay 9, 2023 Eagle Pharmaceuticals EPS ResultsActual EPS$0.44Consensus EPS $0.40Beat/MissBeat by +$0.04One Year Ago EPSN/AEPS Beat Rate4 of last 8 quartersEagle Pharmaceuticals Revenue ResultsActual Revenue$66.31 millionExpected Revenue$63.88 millionBeat/MissBeat by +$2.43 millionYoY Revenue GrowthN/AUpcoming EarningsEagle Pharmaceuticals' next earnings date is estimated for Monday, November 9, 2026, based on past reporting schedules. Conference Call ResourcesCompany Profile Eagle Pharmaceuticals Q1 2023 Earnings FAQ Did Eagle Pharmaceuticals beat earnings estimates for Q1 2023? Eagle Pharmaceuticals (NASDAQ:EGRX) reported earnings of $0.44 per share for Q1 2023, beating the consensus estimate of $0.40. The report was announced on Tuesday, May 9, 2023. What was Eagle Pharmaceuticals' revenue for Q1 2023? Eagle Pharmaceuticals reported revenue of $66.31 million for Q1 2023, against a consensus estimate of $63.88 million. When is Eagle Pharmaceuticals' next earnings date? Eagle Pharmaceuticals' next earnings date is estimated for Monday, November 9, 2026. MarketBeat tracks confirmed and estimated earnings dates for Eagle Pharmaceuticals on the company's earnings history page. Eagle Pharmaceuticals Earnings HeadlinesEagle Pharmaceuticals (NASDAQ:EGRX) Share Price Crosses Above 50-Day Moving Average - What's Next?October 14 at 4:01 AM | americanbankingnews.comEagle Pharmaceuticals Inc.August 27, 2026 | marketwatch.comFederal Reserve Reveals Disturbing New Plan To Control Your MoneyDocket No. OP-1670 is drawing attention for what it reveals about the Federal Reserve's next move. Buried on page 84 is a plan that could expand oversight of checking accounts, purchases, and money transfers across the country. Martin D. Weiss, PhD, founder of Weiss Ratings, breaks down what this document means and why it could roll out as soon as this summer.October 14 at 1:00 AM | Weiss Ratings (Ad)Did Eagle Pharmaceuticals, Inc. Insiders Breach their Fiduciary Duties to Shareholders?April 9, 2026 | prnewswire.comEagle Pharmaceuticals Announces Divestiture of BarhemsysJanuary 14, 2026 | globenewswire.comHALPER SADEH LLC ENCOURAGES EAGLE PHARMACEUTICALS, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTSDecember 24, 2025 | prnewswire.comSee More Eagle Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Eagle Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Eagle Pharmaceuticals and other key companies, straight to your email. Email Address About Eagle PharmaceuticalsEagle Pharmaceuticals (NASDAQ:EGRX) was a specialty pharmaceutical company focused on developing and commercializing injectable and intranasal medicines, with an emphasis on products intended to improve existing therapies through differentiated formulations, dosing approaches, or delivery technologies. The company primarily served hospital, oncology, emergency medicine, and critical-care markets. Eagle’s marketed products included Ryanodex, an injectable formulation of dantrolene sodium used to treat malignant hyperthermia; Belrapzo, a formulation of bendamustine hydrochloride used in certain blood cancers; and Pemfexy, a ready-to-dilute formulation of pemetrexed used in the treatment of certain lung cancers and mesothelioma. Its commercial activities were concentrated mainly in the United States, with selected products and rights supported through external partners in international markets. Founded in 2007, Eagle was led for much of its history by founder and Chief Executive Officer Scott Tarriff. In 2024, Pharmacosmos A/S completed its acquisition of Eagle Pharmaceuticals, and Eagle became part of the Pharmacosmos Group. As a result, Eagle is no longer an independently traded company on the Nasdaq exchange, although its products and pharmaceutical operations continue under its parent organization.View Eagle Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Citi Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenIREN Limited's AI Pivot Gains Traction—But Can Its Data Centers Deliver?PBF Energy's Stunning Rally Faces a Critical TestA Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Albertsons Is Betting on a Turnaround—But Will It Pay Off?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American Business Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
